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18F-FDG PET/CTAbstract Objective: The purpose of this study was to investigate the ability of PET/CT to restage
urinary bladder transitional cell carcinoma (TCC) whether up or down after initial staging by
histopathology and other imaging modalities.
Patients and methods: During three year duration 27 patients with urinary bladder TCC were
prospectively evaluated. They were previously diagnosed by histopathology after biopsy and had
prior imaging for initial staging. All patients underwent PET/CT examinations following a preset
protocol. The images obtained were reconstructed using dedicated software and workstations.
Results of PET/CT examinations were confirmed by histopathology.
Results: Prior imaging and PET/CT findings were matched in 17 patients (63%) with no changes
regarding their initial TNM stages and differed in 10 patients (37%). Six patients (22.2%) showed
new sites of distant metastasis and unchanged initial stages. Two patients (7.4%) were up staged
and 2 patients (7.4%) were down staged for whom the plan of clinical management was justified.
Conclusion: 18F-FDG PET/CT can up and down stage TCC and can detect new sites of nodal or
distant metastasis leading to optimal therapy planning.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Bladder cancer represents 7% of all malignancies in men and
2% of all malignancies in women (1). More than 90% of blad-
der cancers are transitional cell carcinomas (2). Bladder cancer
is usually multifocal and has a high local recurrence rate (3).
At least 50% of the high-grade tumors may have occult meta-
static disease at initial diagnosis (3). Common sites of metas-
tases include the pelvic and retroperitoneal lymph nodes,lungs, liver and bones. Multimodal treatment, depending on
preoperative stage may improve survival (4).
The TNM classification is currently the standard staging
procedure for bladder cancer and is based on clinico-
pathological findings (5). TNM staging system (Table 1) has
become the system of choice primarily because it has the
advantage of distinguishing nodal involvement from locally
advanced tumors and from distant metastatic spread (6).
T staging is best done by cystoscopy and deep biopsy (7).
Identifying nodal disease N is critical because it has profound
implication for treatment plan (6). The incidence of distal
metastasis M increases with increasing T and N stages (8).
Noninvasive imaging plays an important role in all stages of
Table 1 Staging groups of bladder Cancer (5).
Stage T N M
0 Ta or Tis N0 M0
I T1 N0 M0
II T2a or T2b N0 M0
III T3a, T3b or T4a N0 M0
IV T4b N0 M0
Any T N1, N2 or N3 M0 or M1
1096 T.W. Kassembladder cancer. The standard preoperative method for staging
is CT or MRI of the abdomen and pelvis, although these
methods lack sensitivity and, therefore, may not offer an
entirely accurate basis for therapeutic planning (9).
PET/CT with 18F-FDG has emerged as a powerful tool for
the combined metabolic and anatomic evaluation of many can-
cers (10). 18F-FDG uptake by bladder cancer was first demon-
strated by Harney et al. (11) in rats, with an estimated uptake
ratio of tumor to normal bladder of 13:1. Excreted FDG
results in marked uptake throughout the urinary tract and
obscures urologic malignancies. Despite this limitation,
18F-FDG PET/CT was found to be useful in evaluating TCC
primary tumor and distant disease (12) (see Table 2).
The purpose of this study was to investigate the ability of
PET/CT to restage urinary bladder TCC whether up or down
after initial staging by histopathology and other imaging
modalities.
2. Patients and methods
2.1. Patients
A prospective study of 27 patients aged 34–72 years old (with
mean age of 55 years old) presenting to a private specialized
medical center with an initial diagnosis and staging of urinary
bladder TCC coming for restaging between July 2012 and
August 2015 was performed. There were no set criteria for
referral other than histopathologic evidence of TCC after
biopsy and the presence of initial staging by post-contrast CT
examination. Patients had clinical evaluation including medical
history. Information regarding interventional procedures, surg-
eries and histopathology was obtained from all cases.
2.2. Methods
PET/CT scan examination was obtained for each patient. All
patients were scanned using a dedicated PET system (Siemens
Syngo PET VG 50A Biograph 20 VA 44A, Berlin, Germany),Table 2 Distribution of findings in all cases.
No % New
1st group 17 63 –
2nd group 1st subgroup 6 22.2 Yes
2nd subgroup 2 7.4 Yes
3rd subgroup 2 7.4 –
27 100covering an axial field-of-view (FOV) of 15.2 cm and a resolu-
tion of 4 mm axially and 3.8 mm trans axially at the center.
Patients were instructed to fast for at least 8 h before the
intravenous injection of 370–410 MBq of 18F-FDG. Blood glu-
cose was measured before injection of the tracer to ensure glu-
cose blood levels below 120 mg/dl. Before and after injection,
patients were kept sitting comfortably in a quiet room. Saline
infusion (approximately 500 ml) was given before tracer injec-
tion. Whole-body PET/CT images were acquired 40–50 min
after radiotracer injection. CT images were acquired without
breath-holding instructions. The PET emission scan was
obtained immediately after acquisition of the CT scan.
Routine axial imaging consisting of CT of the chest, abdo-
men and pelvis at 5 mm intervals after intravenous non-ionic
contrast administration was performed in all patients.
2.3. Data analysis and interpretation
PET image datasets were reconstructed using the CT data for
attenuation correction and fused images were displayed on a
workstation. Images were reconstructed in coronal and sagittal
multiplanar planes and read visually.
All PET/CT imaging and CT imaging were performed and
evaluated by one staff radiologist with expertise in genitouri-
nary imaging accompanied by one staff nuclear medicine.
Standardized uptake values (SUV) were compared to back-
ground vasculature to determine positivity and all foci of
unphysiologic FDG uptake were considered indicative of meta-
static disease during interpretation of reconstructed PET/CT
images. PET/CT findings were confirmed by histopathology.
3. Results
From July 2012 to August 2015, 27 patients were entered in the
study aged on average 55 years (range, 34–72 years).
All examined cases had malignant urinary bladder masses
proven by histopathology to be TCC. All of them had an ini-
tial staging obtained after performing post-contrast CT
examination.
Prior imaging and PET/CT findings matched in 17 patients
(63%) and differed in 10 patients (37%). So, the patients were
classified into two groups: the first group consists of 17 patients
had the same stage given before performing the PET/CT exam-
ination and the second group consists of 10 patients showing
different findings and was subdivided into three subgroups.
The first subgroup consists of 6 patients (22.2%) showing
new sites of distant metastasis detected by current PET/CT
examination; however, the final stage did not change. One
patient showed newly discovered active supraclavicular lymph





Fig. 1 62 years old male patient with urinary bladder mass (TCC). The administered activity is 370.4 MBq. 18F-FDG, blood glucose
level (BGL) was 89 mg/dL. (A) Axial, coronal and sagittal post-contrast CT images, (B) axial, coronal and sagittal MIP PET images, (C)
axial, coronal and sagittal fused PET/CT images showing increased FDG uptake corresponding to enhanced lesion along the left lateral
surface of the urinary bladder (arrows). It measures about 1.6  0.7 cm in diameters with SUVmax 14.6. (D) Axial fused PET/CT images
showing multiple active left supraclavicular groups measuring about 2.8 cm with SUVmax 8.3. Multiple active bilateral common iliac
lymph nodes are seen largest measuring about 2.6 cm in diameter with SUVmax 6.5. Multiple active left para aortic lymph nodes are seen
largest measuring about 1.6 cm in diameter with SUVmax 8.7.
Up and down staging of TCC 1097(stage IV) (Fig. 1). Two patients showed newly discovered
active cervical and mediastinal lymph nodes and their primary
stage was not changed T3aN3M1 and T2bN3M1 (stage IV)
(Fig. 2). One patient showed evidence of pelvic vascular infil-
tration and its primary stage was the same T2aN2M1 (stage
IV) (Fig. 3). Multiple new sites of metastatic bony and hepatic
deposits were detected in two patients and these findings did
not affect their primary stage T4bN3M1 (stage IV) (Fig. 4).
The second subgroup consists of 2 patients (7.4%) who
were up staged after performing PET/CT. One patient showed
newly discovered active common iliac lymph node changing its
stage from T4aN0M0 (stage III) to T4aN3M0 (stage IV)
(Fig. 5). The second patient showed newly discovered active
mediastinal lymph nodes and few lumbar vertebrae active
osseous metastatic deposits changing its stage from
T3aN0M0 (stage III) to T3aN0M1 (stage IV) (Fig. 6).Adjuvant systemic chemotherapy was added to the plan of
management for these patients.
The third subgroup consists of 2 patients (7.4%) who were
down staged after performing PET/CT (Fig. 7). They had
external iliac lymph nodes showing no FDG uptake by PET/
CT and containing no malignant cells by histopathology.
These lymph nodes were diagnosed as metastatic nodes by
prior examinations. Their staging changed from T2aN1M0
(stage IV) to T2aN0M0 (stage II) in the first case and from
T1N1M0 (stage IV) to T1N0M0 (stage I) in the second case.
There was no need for adjuvant therapy for these patients as
was planned before.
The plan of management was adjusted for patients
participating in subgroups 2 and 3 (4 patients, 14.8%) either
by adding needed or by omitting unnecessary systemic
chemotherapy.
Fig. 2 64 years old male patient with urinary bladder mass (TCC). The administered activity is 379 MBq. 18F-FDG, BGL was 92 mg/dL.
(A) Axial fused PET/CT and post-contrast CT image showing numerous active para-aortic lymph nodes largest measuring about 3.0 cm in
diameter with SUVmax 11.8. (B) Axial fused PET/CT and post-contrast CT image showing bilateral internal iliac enlarged active lymph
nodes, the largest at the left internal iliac group measuring about 4.7 cm in diameter with SUVmax 18.5. (C) Axial fused PET/CT and
post-contrast CT image showing multiple hypodense hepatic focal lesions. The largest and most active is seen panning across segment
VI–VII with SUVmax 12.9. (D) Whole body coronal MIP PET image showing enlarged active cervical (left levels IV and V) lymph nodes,
the most active is seen at left supra-clavicular region (arrow) (2.3 cm & SUVmax 10.7). Posterior mediastinal active retro-cardiac LN is
seen measuring 2.5 cm with SUVmax 11.7 (curved arrow). Multiple FDG-avid lesions are seen within right pubic bone, sacrum and
vertebrae. The most active lesion is seen in L1 (SUVmax 10.6).
Fig. 3 55 years old male patient with urinary bladder mass (TCC). The administered activity is 407 MBq. 18F-FDG, BGL was 102 mg/
dL. (A–C) axial fused PET/CT images. Image (A) shows a metabolically active ill defined soft tissue lesion obliterating the right semino-
vesical angle merging with the urinary bladder wall and the dome of the prostate (SUV max 4.4). Image (B) shows distended related pelvic
vein draining into the right internal iliac vein and showing increased FDG uptake (SUV max 6.9), denoting infiltration (arrows). Image
(C) shows multiple metabolically active left external iliac lymph nodes (maximum SUV 6.8 over 1.1 cm lymph node) and left internal iliac
lymph nodes (maximum SUV 6.3 over 1.3 cm lymph node).
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Bladder carcinoma is the most frequent type of tumor of the
urinary tract and is most prevalent in the fifth to seventh dec-
ade of life (13). Approximately 70% of bladder cancers present
as superficial tumors, which tend to recur, and 30% present as
muscle-invasive disease associated with a high risk of death
from distant metastases (14). Optimal therapy planning is
dependent on accurate staging of the bladder tumor. For iden-
tification of patients with metastatic disease, current imaging
techniques including sonography, computed tomography
(CT) and magnetic resonance imaging (MRI) have not provenFig. 4 47 years old male patient with urinary bladder mass (TCC). Th
(A) Axial post-contrast CT, PET and fused PET/CT images showing m
lesion is seen in the left lobe with SUVmax 8.2. (B) Axial post-contrast
lesions at the sacrum and pelvic bones (SUVmax 13.0 over the sacrum
showing wide spread hypermetabolic lesions at the sternum and verteto be highly accurate (15). 18F-FDG PET/CT has become an
important noninvasive imaging modality for many malignan-
cies because of its unique capability to image metabolically
active lesions (16).
Patil et al. (17) found that 18F-FDG PET/CT of transi-
tional cell carcinoma can be useful in evaluating the primary
tumor and distant disease while Swinen et al. (18) stated that
PET/CT provides good diagnostic accuracy of lymph node
staging of bladder cancer.
Liu et al. (19) included 46 patients for examination of
FDG-PET in staging of locoregional and distant metastases
in bladder cancer. Their results were more in favor of PET/e administered activity is 398 MBq. 18F-FDG, BGL was 99 mg/dL.
ultiple ill defined hepatic hypermetabolic lesions. The most active
CT, PET and fused PET/CT images showing hypermetabolic lytic
). (C) Sagittal post-contrast CT, fused PET/CT and PET images
brae (SUVmax 13.6 over T1).
Fig. 5 63 years old female patient with urinary bladder mass underwent cystoscopic and histopathology revealed (TCC). The
administered activity is 395 MBq. 18F-FDG, BGL was 110 mg/dL. (A–C) Multiplanar fused PET/CT and post-contrast CT images
showing FDG-avid soft tissue thickening in the postero-inferior aspect of the urinary bladder being inseparable from another soft tissue
thickening involving the vaginal vault with obliteration of the vesico-vaginal fat planes (SUVmax 11.2). (D) Axial fused PET/CT and post-
contrast CT image showing hypermetabolic left common iliac lymph node is seen (arrow)measuring about 1.5 cm diameter with SUVmax
5.4.
1100 T.W. KassemCT, showing a sensitivity of 77%, a specificity of 97%, and an
accuracy of 89% to reveal metastatic TCC.
Accurate assessment of local tumor extent and nodal dis-
ease is particularly important in treatment planning. Patients
with superficial tumor may be treated with transurethral resec-
tion with or without intravesical chemotherapy. Those with
more invasive but still localized tumor (T2 or T3) benefit from
partial or radical cystectomy, or a combination of radiationand systemic chemotherapy. Patients with unresectable tumors
(T4b) or local or distant metastases should receive systemic
chemotherapy (20).
This study showed surprising results regarding detection of
distant metastasis as 7 patients out of 27 showed newly
detected sites of distant metastasis representing 25.9% of
patients. Six patients had no change regarding their stages
while 1 patient was up staged from stage III to stage IV. This
Fig. 6 58 years old male patient with urinary bladder mass (TCC). The administered activity is 371 MBq. 18F-FDG, BGL was 95 mg/dL.
(A–C) Axial post-contrast CT, PET and fused PET/CT images showing hypermetabolic subcarinal lymph node measuring about 1.5 cm in
diameter (SUVmax 8.3) and multiple hypermetabolic bony deposits at the lower dorsal and lumbar vertebral bodies.
Fig. 7 60 years old male patient with urinary bladder mass (TCC). The administered activity is 381 MBq. 18F-FDG, BGL was 101 mg/
dL. (A–C) Axial post-contrast CT, PET and fused PET/CT images showing left external iliac lymph node measuring about 1.2 cm in
diameter. No evidence of FDG uptake was noted.
Up and down staging of TCC 1101agrees with Drieskens et al. (21) who examined the value of
preoperative FDG-PET/CT in identifying locoregional lymph
node metastasis and other distant metastasis in 55 patients
with bladder cancer and concluded that PET/CT creates an
advantage for distant metastases but, compared with CT, there
was no advantage for the detection of locoregional metastasis.
Swinen and colleagues (18) studied 51 patients and indi-
cated that the sensitivity of CT alone and of FDG-PET/CT
for the detection of regional lymph node metastasis is equal.
This findings matches with the current study that showed that
loco-regional lymph staging could be decided based on priorimaging information alone, without new additional benefit
from the PET/CT examination other than the advantage of
precisely localizing the hypermetabolic nodes. One patient
belonging to subgroup 2 in second group had a change regard-
ing his N staging after detection of active common iliac lymph
node (from N0 to N3).
PET/CT affected the clinical management in 6 out of 35
patients (17% of total), by prompting additional therapy in
5 patients and a wait-and-watch strategy in 1 patient in a study
done by Jadvar and colleagues (22) who reported the detection
of unsuspected nodal and skeletal metastasis. When Drieskens
1102 T.W. Kassemet al. (21) used PET/CT for the preoperative staging of inva-
sive bladder carcinoma, they found that the addition of
PET/CT to conventional imaging changed staging in 15% of
the patients. The results of these two studies were very close
to the current study in which the plan of management changed
in 4 out of 27 patients representing 14.8% of cases.
Although FDG-PET/CT seems promising for combining
metabolic and anatomic diagnosis for the detection of metasta-
sis in pelvic malignancy, its use, especially in bladder malig-
nancy has been hampered by technical limitations and
urinary excretion (23). Several interventions such as adequate
hydration, bladder irrigation and forced diuresis have been
used to overcome this obstacle.
PET/CT is still limited in its spatial resolution. Another
problem is the faint FDG uptake by some tumors. This behav-
ior is attributed to high activity of glucose-6-phosphatase, the
enzyme that converts F-FDG-6-phosphate back into F-FDG
with its excretion from the tumor cells. The use of other
PET tracers, such as C11-methionine and C11-choline, are cur-
rent possibilities, but the short half-lives of these tracers
restrict their routine use.
To avoid radical surgery in incurable patients or toxic
chemotherapy in patients without metastasis, accurate staging
is of utmost importance. As a metabolic and anatomic diag-
nostic tool, 18F-FDG PET/CT has the ability to change plan
of management in patients with known TCC. This study adds
to the current data that suggest that PET/CT may improve the
imaging evaluation of these patients, affect the decision mak-
ing and ameliorate long term outcomes.
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